The Experts below are selected from a list of 321 Experts worldwide ranked by ideXlab platform

Yusaku Nakamura - One of the best experts on this subject based on the ideXlab platform.

  • Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson’s Disease
    Dysphagia, 2015
    Co-Authors: Makito Hirano, Chiharu Isono, Hikaru Sakamoto, Shuichi Ueno, Susumu Kusunoki, Yusaku Nakamura
    Abstract:

    Abnormal swallowing, dysphagia, is a potentially fatal symptom in Parkinson’s disease (PD) and is characterized by frequent silent aspiration, an unrecognized risk of suffocation and aspiration pneumonia. Several studies have reported that the injection of apomorphine, a Dopamine Agonist, alleviated dysphagia in some patients with PD. The effects of other antiparkinson medications against dysphagia remain controversial. Rotigotine is another Dopamine Agonist with non-oral administration, i.e., a transdermal patch. Its noninvasiveness seems to render this medicine even more suitable than apomorphine for dysphasic patients. However, no direct evidence has been reported. In the present retrospective open-label study, we for the first time objectively showed that rotigotine improved swallowing on videofluoroscopic examination in dysphagic patients with PD.

  • rotigotine transdermal patch improves swallowing in dysphagic patients with parkinson s disease
    Dysphagia, 2015
    Co-Authors: Makito Hirano, Chiharu Isono, Hikaru Sakamoto, Shuichi Ueno, Susumu Kusunoki, Yusaku Nakamura
    Abstract:

    Abnormal swallowing, dysphagia, is a potentially fatal symptom in Parkinson's disease (PD) and is characterized by frequent silent aspiration, an unrecognized risk of suffocation and aspiration pneumonia. Several studies have reported that the injection of apomorphine, a Dopamine Agonist, alleviated dysphagia in some patients with PD. The effects of other antiparkinson medications against dysphagia remain controversial. Rotigotine is another Dopamine Agonist with non-oral administration, i.e., a transdermal patch. Its noninvasiveness seems to render this medicine even more suitable than apomorphine for dysphasic patients. However, no direct evidence has been reported. In the present retrospective open-label study, we for the first time objectively showed that rotigotine improved swallowing on videofluoroscopic examination in dysphagic patients with PD.

Makito Hirano - One of the best experts on this subject based on the ideXlab platform.

  • Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson’s Disease
    Dysphagia, 2015
    Co-Authors: Makito Hirano, Chiharu Isono, Hikaru Sakamoto, Shuichi Ueno, Susumu Kusunoki, Yusaku Nakamura
    Abstract:

    Abnormal swallowing, dysphagia, is a potentially fatal symptom in Parkinson’s disease (PD) and is characterized by frequent silent aspiration, an unrecognized risk of suffocation and aspiration pneumonia. Several studies have reported that the injection of apomorphine, a Dopamine Agonist, alleviated dysphagia in some patients with PD. The effects of other antiparkinson medications against dysphagia remain controversial. Rotigotine is another Dopamine Agonist with non-oral administration, i.e., a transdermal patch. Its noninvasiveness seems to render this medicine even more suitable than apomorphine for dysphasic patients. However, no direct evidence has been reported. In the present retrospective open-label study, we for the first time objectively showed that rotigotine improved swallowing on videofluoroscopic examination in dysphagic patients with PD.

  • rotigotine transdermal patch improves swallowing in dysphagic patients with parkinson s disease
    Dysphagia, 2015
    Co-Authors: Makito Hirano, Chiharu Isono, Hikaru Sakamoto, Shuichi Ueno, Susumu Kusunoki, Yusaku Nakamura
    Abstract:

    Abnormal swallowing, dysphagia, is a potentially fatal symptom in Parkinson's disease (PD) and is characterized by frequent silent aspiration, an unrecognized risk of suffocation and aspiration pneumonia. Several studies have reported that the injection of apomorphine, a Dopamine Agonist, alleviated dysphagia in some patients with PD. The effects of other antiparkinson medications against dysphagia remain controversial. Rotigotine is another Dopamine Agonist with non-oral administration, i.e., a transdermal patch. Its noninvasiveness seems to render this medicine even more suitable than apomorphine for dysphasic patients. However, no direct evidence has been reported. In the present retrospective open-label study, we for the first time objectively showed that rotigotine improved swallowing on videofluoroscopic examination in dysphagic patients with PD.

Ray K Chaudhuri - One of the best experts on this subject based on the ideXlab platform.

  • crystallisation within transdermal rotigotine patch is there cause for concern
    Expert Opinion on Drug Delivery, 2008
    Co-Authors: Ray K Chaudhuri
    Abstract:

    Rotigotine transdermal patch is the first transdermal non-ergot Dopamine Agonist, being a selective Dopamine D1/D2/D3 receptor Agonist [1-4]. Rotigotine patch is effective over 24 h and provides a ...

  • transdermal rotigotine a new non ergot Dopamine Agonist for the treatment of parkinson s disease
    Expert Opinion on Drug Delivery, 2007
    Co-Authors: Y Naidu, Ray K Chaudhuri
    Abstract:

    An important conceptual development to avoid the occurrence of motor dyskinesias in Parkinson’s disease is continuous Dopaminergic stimulation. Studies in animal models and humans suggest that continuous Dopaminergic stimulation could be achieved by the infusions of different Dopamine Agonists or levodopa, and may significantly reduce the risk of dyskinesias associated with treatment strategies utilising pulsatile treatment options. However, so far, these techniques have either necessitated frequent intake of oral therapy or invasive parenteral treatment. The rotigotine transdermal delivery system represents a significant development that allows a constant delivery of a non-ergot Dopamine Agonist using a once-daily regimen, achieving steady plasma levels. Clinical trials demonstrate the efficacy of rotigotine in early and advanced Parkinson’s disease, with important implications for treatment of non-motor symptoms of Parkinson’s disease.

Chiharu Isono - One of the best experts on this subject based on the ideXlab platform.

  • Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson’s Disease
    Dysphagia, 2015
    Co-Authors: Makito Hirano, Chiharu Isono, Hikaru Sakamoto, Shuichi Ueno, Susumu Kusunoki, Yusaku Nakamura
    Abstract:

    Abnormal swallowing, dysphagia, is a potentially fatal symptom in Parkinson’s disease (PD) and is characterized by frequent silent aspiration, an unrecognized risk of suffocation and aspiration pneumonia. Several studies have reported that the injection of apomorphine, a Dopamine Agonist, alleviated dysphagia in some patients with PD. The effects of other antiparkinson medications against dysphagia remain controversial. Rotigotine is another Dopamine Agonist with non-oral administration, i.e., a transdermal patch. Its noninvasiveness seems to render this medicine even more suitable than apomorphine for dysphasic patients. However, no direct evidence has been reported. In the present retrospective open-label study, we for the first time objectively showed that rotigotine improved swallowing on videofluoroscopic examination in dysphagic patients with PD.

  • rotigotine transdermal patch improves swallowing in dysphagic patients with parkinson s disease
    Dysphagia, 2015
    Co-Authors: Makito Hirano, Chiharu Isono, Hikaru Sakamoto, Shuichi Ueno, Susumu Kusunoki, Yusaku Nakamura
    Abstract:

    Abnormal swallowing, dysphagia, is a potentially fatal symptom in Parkinson's disease (PD) and is characterized by frequent silent aspiration, an unrecognized risk of suffocation and aspiration pneumonia. Several studies have reported that the injection of apomorphine, a Dopamine Agonist, alleviated dysphagia in some patients with PD. The effects of other antiparkinson medications against dysphagia remain controversial. Rotigotine is another Dopamine Agonist with non-oral administration, i.e., a transdermal patch. Its noninvasiveness seems to render this medicine even more suitable than apomorphine for dysphasic patients. However, no direct evidence has been reported. In the present retrospective open-label study, we for the first time objectively showed that rotigotine improved swallowing on videofluoroscopic examination in dysphagic patients with PD.

Hikaru Sakamoto - One of the best experts on this subject based on the ideXlab platform.

  • Rotigotine Transdermal Patch Improves Swallowing in Dysphagic Patients with Parkinson’s Disease
    Dysphagia, 2015
    Co-Authors: Makito Hirano, Chiharu Isono, Hikaru Sakamoto, Shuichi Ueno, Susumu Kusunoki, Yusaku Nakamura
    Abstract:

    Abnormal swallowing, dysphagia, is a potentially fatal symptom in Parkinson’s disease (PD) and is characterized by frequent silent aspiration, an unrecognized risk of suffocation and aspiration pneumonia. Several studies have reported that the injection of apomorphine, a Dopamine Agonist, alleviated dysphagia in some patients with PD. The effects of other antiparkinson medications against dysphagia remain controversial. Rotigotine is another Dopamine Agonist with non-oral administration, i.e., a transdermal patch. Its noninvasiveness seems to render this medicine even more suitable than apomorphine for dysphasic patients. However, no direct evidence has been reported. In the present retrospective open-label study, we for the first time objectively showed that rotigotine improved swallowing on videofluoroscopic examination in dysphagic patients with PD.

  • rotigotine transdermal patch improves swallowing in dysphagic patients with parkinson s disease
    Dysphagia, 2015
    Co-Authors: Makito Hirano, Chiharu Isono, Hikaru Sakamoto, Shuichi Ueno, Susumu Kusunoki, Yusaku Nakamura
    Abstract:

    Abnormal swallowing, dysphagia, is a potentially fatal symptom in Parkinson's disease (PD) and is characterized by frequent silent aspiration, an unrecognized risk of suffocation and aspiration pneumonia. Several studies have reported that the injection of apomorphine, a Dopamine Agonist, alleviated dysphagia in some patients with PD. The effects of other antiparkinson medications against dysphagia remain controversial. Rotigotine is another Dopamine Agonist with non-oral administration, i.e., a transdermal patch. Its noninvasiveness seems to render this medicine even more suitable than apomorphine for dysphasic patients. However, no direct evidence has been reported. In the present retrospective open-label study, we for the first time objectively showed that rotigotine improved swallowing on videofluoroscopic examination in dysphagic patients with PD.